GleamWall
中文EN

IMUX IMMUNIC, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1280776 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY135.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-223.2%
ROA-144.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.4%
Debt / equity0.00x
Current ratio4.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-36.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$81.98M$80.05M
SG&A expense$21.25M$18.01M
Operating income-$103.23M-$98.05M
Income tax$0—
Net income-$97.17M-$100.51M
EBITDA-$103.06M-$97.92M
EPS (basic)-0.62-1.00
EPS (diluted)-0.62-1.00
Dividends declared per share0.000.00
Weighted avg. shares (diluted)155.69M100.17M
Banking
Provision for credit losses$497,000$234,000
Balance sheet
Cash & equivalents$15.48M$35.67M
Current assets$22.87M$39.33M
PP&E, net$608,000$545,000
Total assets$24.05M$40.87M
Current liabilities$30.62M$22.18M
Total liabilities$30.73M$22.44M
Shareholders' equity-$6.67M$18.43M
Shares outstanding15.88M90.15M
Cash flow statement
Operating cash flow-$85.81M-$84.77M
Capital expenditure$161,000$264,000
Free cash flow-$85.97M-$85.03M
Investing cash flow-$161,000-$264,000
Financing cash flow$65.58M$74.54M
Depreciation & amortization$168,000$134,000
Stock-based compensation$8.86M$8.53M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.